Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2000
11/30/2000WO2000071703A2 Inhibition of histone deacetylase
11/30/2000WO2000071571A2 Fap-activated anti-tumor compounds
11/30/2000WO2000071561A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics
11/30/2000WO2000071560A1 Methods of modulating activity of prokaryotic ribosomes
11/30/2000WO2000071535A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
11/30/2000WO2000071534A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents
11/30/2000WO2000071153A2 Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors
11/30/2000WO2000071150A1 Tumor necrosis factor receptor 5
11/30/2000WO2000071148A2 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
11/30/2000WO2000071146A2 Glutathione reductase for therapy and prophylaxis of aids
11/30/2000WO2000071137A1 Electrolyte gels for maintaining hydration and rehydration
11/30/2000WO2000071135A1 Anti-tumor comprising boroproline compounds
11/30/2000WO2000071132A1 Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance
11/30/2000WO2000071126A1 Quinoxaline containing medicaments for post exposure prophylaxis of an hiv infection
11/30/2000WO2000071121A1 Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations
11/30/2000WO2000071113A1 Methods of treating proliferative disorders
11/30/2000WO2000071109A2 Pharmaceutical compositions comprising s-(+) -desmethylselegiline for the treatment of withdrawal
11/30/2000WO2000071107A2 New pharmaceutical combinations for nos inhibitors
11/30/2000WO2000071103A2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
11/30/2000WO2000071101A2 Methods and compounds for inhibiting amyloid deposits
11/30/2000WO2000071100A1 Device and method for increasing the transdermal permeation of medicaments
11/30/2000WO2000071099A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/30/2000WO2000049993A3 Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
11/30/2000WO2000047611A3 Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
11/30/2000WO2000047610A3 Method for altering undesirable immune responses to polypeptides
11/30/2000WO2000045832A3 Regulation of anaesthesia
11/30/2000WO2000044404A3 Methods for inhibiting brain tumor growth by using selected integrin antagonists
11/30/2000WO2000044379A3 Methods for restoring and/or enhancing accommodation in pseudo phakia
11/30/2000WO2000043790A3 Compositions and methods for the diagnosis and treatment of tumor
11/30/2000WO2000043028A3 Method of treating chronic cardiac disease
11/30/2000WO2000043014A3 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
11/30/2000WO2000042989A3 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
11/30/2000WO2000042201A3 Human peptidases
11/30/2000WO2000042172A3 Human homologues of proteins regulated by circadian rhythms
11/30/2000WO2000041692A3 Compositions having improved stability
11/30/2000WO2000040269A3 Pharmaceutical compositions for treatment of diseased tissues
11/30/2000WO2000040241A3 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
11/30/2000WO2000038716A9 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
11/30/2000WO2000035434A3 Compositions and methods for the treatment of anorectal disorders
11/30/2000WO2000034481A3 DRUG TARGETS IN $i(CANDIDA ALBICANS)
11/30/2000WO2000033814A3 Method for administering agents to the central nervous system
11/30/2000WO2000029846A3 COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-α MEDIATED PATHWAY
11/30/2000WO2000027363A9 Aerosols comprising nanoparticle drugs
11/30/2000WO2000025829A3 Radiodense compositions
11/30/2000WO2000024391A3 Conductance of improperly folded proteins through the secretory pathway
11/30/2000WO2000021572A3 Hydrogels and water soluble polymeric carriers for drug delivery
11/30/2000DE19923961A1 Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
11/30/2000CA2698347A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
11/30/2000CA2684016A1 Methods and compounds for inhibiting amyloid deposits
11/30/2000CA2384287A1 Methods of treating proliferative disorders
11/30/2000CA2375032A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics
11/30/2000CA2374918A1 Identification of novel mechanisms of drug resistance
11/30/2000CA2374677A1 Pharmaceutical compositions comprising desmethyselegiline for the treatment of drug withdrawal
11/30/2000CA2374674A1 Tumor necrosis factor receptor 5
11/30/2000CA2374668A1 New pharmaceutical combinations for nos inhibitors
11/30/2000CA2374531A1 Diagnostics and therapeutics for restenosis
11/30/2000CA2374520A1 Secreted alpha-helical protein - 32
11/30/2000CA2374507A1 Assay for the detection of paclitaxel resistant cells in human tumors
11/30/2000CA2374432A1 Dna encoding a human subunit of the 5-ht3 serotonin receptor
11/30/2000CA2374301A1 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
11/30/2000CA2373793A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents
11/30/2000CA2373643A1 Anti-tumor comprising boroproline compounds
11/30/2000CA2373588A1 Gene therapy of pulmonary disease
11/30/2000CA2373285A1 Diagnosis and treatment of atherosclerosis and coronary heart disease
11/30/2000CA2372567A1 Indole-type derivatives as inhibitors of p38 kinase
11/30/2000CA2369933A1 Fap-activated anti-tumor compounds
11/30/2000CA2366408A1 Inhibition of histone deacetylase
11/29/2000EP1055426A1 Dysuria remedies
11/29/2000EP1055366A1 Use of transgenic mice lacking jun-b expression in the myeloid lineage
11/29/2000EP1054998A1 Transglutaminase linkage of agents to tissue
11/29/2000EP1054995A1 GABAB-R2a, A 7TM RECEPTOR
11/29/2000EP1054981A2 Prostate-associated serine protease
11/29/2000EP1054979A1 Compositions and methods for sensitizing and inhibiting growth of human tumor cells
11/29/2000EP1054962A2 Caf1-related protein
11/29/2000EP1054961A2 Human short-chain tnf-receptor family protein
11/29/2000EP1054953A1 NOVEL pgsA
11/29/2000EP1054899A2 AGENTS FOR TREATING HUMAN ILLNESSES BASED ON $g(b)-CATENIN, AND THE PRODUCTION AND USE THEREOF
11/29/2000EP1054693A1 Inhibitors of complement activation
11/29/2000EP1054688A1 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses
11/29/2000EP1054683A1 Modified heat shock protein-antigenic peptide complex
11/29/2000EP1054681A1 The use of combinations of active agents consisting of antimicrobially active substances and plant extracts containing terpene in veterinary medicine
11/29/2000EP1054664A1 Method for modulating macrophage activation
11/29/2000EP1054633A1 Apparatus and method for inhibiting restenosis by applying ultrasound energy together with drugs
11/29/2000EP1054594A1 Inotropic and diuretic effects of exendin and glp-1
11/29/2000EP1054591A1 Improved extracorporeal methods for enhancing antigen presentation and immune responsiveness
11/29/2000CN1275085A Cytolysis of target cell, reagent and composition for cytolysis and compound for preparing these reagents
11/29/2000CN1275080A Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
11/28/2000US6153653 Choline compositions and uses thereof
11/28/2000US6153647 Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
11/28/2000US6153644 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
11/28/2000US6153632 Method and composition for the treatment of diabetes
11/28/2000US6153620 Opiate receptor antagonist modulates movement disorder
11/28/2000US6153615 Administering nitric oxide synthesis inhibiting amount of dihydrofolate reductase inhibitor, catecholamine replacing non-toxic amount of levodopa with or without carbidopa and serotonin replacing non-toxic amount of l-5-hydroxytryptophane
11/28/2000US6153597 For gene therapy such as in vitro, ex vivo and/or in vivo transfer of genetic material
11/28/2000US6153587 Conformationally constrained LH-RH analogues, their uses and pharmaceutical compositions containing them
11/28/2000US6153430 Used as indicator of the presence of ovarian cancer tumor cells
11/28/2000US6153396 Drug screening by adding compound to mixture of chaperone and pilus subunit and determining the change in binding; bactericides for urinary tract infections
11/28/2000US6153220 Taste-masked formulations
11/28/2000US6153217 Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
11/28/2000US6153200 Administering an isolated and purified bacterial dnajp1 peptide having the amino acid sequence
1 ... 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 ... 1151